139 related articles for article (PubMed ID: 27909271)
1. [Epidermal Growth Factor Receptor-mutated Advanced Lung Adenocarcinoma with Long-term Tumor-free Survival by Chemotherapy Followed by Tyrosine Kinase Inhibitor Treatment after Reduction Surgery].
Morio A; Nakahara K; Futagawa T; Suzuki K
Kyobu Geka; 2016 Dec; 69(13):1051-1054. PubMed ID: 27909271
[TBL] [Abstract][Full Text] [Related]
2. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
[TBL] [Abstract][Full Text] [Related]
3. [A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma].
Chen WQ; Li P; Wang Q; Zhang YJ; Li HY; Jin XT; Yan S; Kou GF; Cai SL; Liu G
Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):133-137. PubMed ID: 29502374
[No Abstract] [Full Text] [Related]
4. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S
World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665
[TBL] [Abstract][Full Text] [Related]
5. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
6. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
7. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
8. EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma.
Koh Y; Jang B; Jeon YK; Kim TM; Lee SH; Kim DW; Chung DH; Kim YT; Kim YW; Heo DS
Jpn J Clin Oncol; 2011 Apr; 41(4):548-54. PubMed ID: 21247966
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Kitade H; Yamada T; Igarashi S; Hokkoku K; Mori M; Shintaku K; Sagawa M; Nakai M; Yano S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):79-81. PubMed ID: 23306923
[TBL] [Abstract][Full Text] [Related]
10. [A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib].
Morio A; Ninomiya H; Sunada K
Gan To Kagaku Ryoho; 2011 Feb; 38(2):279-81. PubMed ID: 21368495
[TBL] [Abstract][Full Text] [Related]
11. Study of gefitinib maintenance in unselected patients with metastatic primary lung adenocarcinoma: A descriptive study.
Kumar R; Dubashi B; Kayal S; Lazzar SC; Barathi D; Kumar V
Indian J Cancer; 2017; 54(1):188-192. PubMed ID: 29199688
[TBL] [Abstract][Full Text] [Related]
12. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
13. Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature.
Marech I; Vacca A; Gnoni A; Silvestris N; Lorusso V
Tumori; 2013; 99(5):e241-4. PubMed ID: 24362878
[TBL] [Abstract][Full Text] [Related]
14. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
Han B; Jin B; Chu T; Niu Y; Dong Y; Xu J; Gu A; Zhong H; Wang H; Zhang X; Shi C; Zhang Y; Zhang W; Lou Y; Zhu L; Pei J
Int J Cancer; 2017 Sep; 141(6):1249-1256. PubMed ID: 28560853
[TBL] [Abstract][Full Text] [Related]
15. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
16. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
[TBL] [Abstract][Full Text] [Related]
17. Post-recurrence survival analysis of stage I non-small-cell lung cancer.
Lee K; Kim HR; Kim DK; Kim YH; Park SI; Choi SH; Han J
Asian Cardiovasc Thorac Ann; 2017 Nov; 25(9):623-629. PubMed ID: 29058973
[TBL] [Abstract][Full Text] [Related]
18. Clinical profile and outcomes of patients with Stage IV adenocarcinoma of lung: A tertiary cancer center experience.
Paliwal P; Rajappa S; Santa A; Mohan M; Murthy S; Lavanya N
Indian J Cancer; 2017; 54(1):197-202. PubMed ID: 29199690
[TBL] [Abstract][Full Text] [Related]
19. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
Chiari R; Duranti S; Ludovini V; Bellezza G; Pireddu A; Minotti V; Bennati C; Crinò L
J Clin Oncol; 2014 Mar; 32(9):e30-2. PubMed ID: 24419120
[No Abstract] [Full Text] [Related]
20. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]